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Abstract:  The term "vulnerable plaque" refers to a vascular lesion that is prone to rupture and may result in life-
threatening events which include myocardial infarction. It consists of thin-cap fibroatheroma and a large lipid core which 
is highly thrombogenic. Acute coronary syndromes often result from rupture of vulnerable plaques which frequently are 
only moderately stenosed and not visible by conventional angiography. Several invasive and non-invasive strategies have 
been developed to assess the burden of vulnerable plaques. Intravascular ultrasound provides a two-dimensional cross-
sectional image of the arterial wall and can help assess the plaque burden and composition. Optical coherent tomography 
offers superior resolution over intravascular ultrasound. High-resolution magnetic resonance imaging provides non-invasive 
imaging for visualizing fibrous cap thickness and rupture in plaques. In addition, it may be of value in assessing the  
effects of treatments, such as lipid-lowering therapy. Technical issues however limit its clinical applicability. The role of 
multi-slice computed tomography, a well established screening tool for coronary artery disease, remains to be determined. 
Fractional flow reserve (FFR) may provide physiological functional assessment of plaque vulnerability; however, its  
role in the management of vulnerable plaque requires further studies. Treatment of the vulnerable patient may involve  
systemic therapy which currently include statins, ACE inhibitors, beta-blockers, aspirin, and calcium-channel blockers 
and in the future local therapeutic options such as drug-eluting stents or photodynamic therapy. 
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INTRODUCTION 
  Atherosclerosis is a systemic disease of the vessel wall. 
The main components of the atherosclerotic plaque are 
connective tissue extracellular matrix, including collagen, 
proteoglycans, and fibronectin elastic fibers; cholesterol, 
cholesteryl esters, and phospholipids; and cells such as 
monocyte-derived macrophages, T lymphocytes, and smooth 
muscle cells. Varying proportions of these components occur 
in different plaques, giving rise to a spectrum of lesions [1, 
2]. The term vulnerable plaque is used to describe a plaque at 
high risk of disruption leading to thrombosis. Vulnerable 
plaques tend to have a thin fibrous cap and a large lipid core 
which is highly thrombogenic [3, 4]. Acute coronary 
syndromes often result from rupture of these angiograpically 
mildly stenosed lesions. The caps are often thinnest at   
the shoulder region, where macrophages and mast cells 
accumulate. In addition there is a large lipid core rich   
in cholesterol, also containing cholesteryl esters which 
facilitate plaque softening. A negative relation exists 
between temperature and core stiffness. If temperature 
increases, as in inflammation, the core becomes softer. A 
soft core may be more vulnerable to rupture as it may not be 
able to withstand the imposed circumferential stress, which 
is then redistributed to the fibrous cap [5-7]. It is well   
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recognised that a haemodynamically non-significant 
coronary plaque can rupture and produce a cardiac event 
long before it produces significant lumen narrowing and 
symptoms of angina. 
  Attempts have been made to predict individual risk of 
development of severe atheroscelerosis from population-
based risk factors studies. Traditional cardiovascular risk 
factors including age, gender, body mass index, diabetes, 
hypertension, smoking, lipid profile and family history of 
premature coronary artery disease have been established over 
the last 60 years from population-based studies such as the 
Framingham heart study and the Prospective Cardiovascular 
Munster (PROCAM) study [8, 9]. However, a recent 
retrospective study of the utility of the National Cholesterol 
Education Program (NCEP) III guidelines in a group of 
young adults (age <or=55 years for men and <or=65 years 
for women), reported that only, 25% of the patients who had 
recently experienced acute myocardial infarction met the 
criteria for pharmacological therapy [10]. Consequently 
many additional tools and scoring systems exist to help 
identify patients at risk not only of developing cardiovas- 
cular disease but acute coronary syndromes. This manuscript 
reviews current concepts of the vulnerable plaque and patient 
and discuss diagnosis and current and future treatment   
options. 
The Concept of Vulnerable Plaque and Patient 
  Vulnerable plaques may result in vulnerable high–risk 
patients. This concept has recently been discussed by Na-
ghavi et al. in a consensus document which concluded the 124    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Liang et al. 
following [11-13]. Firstly rupture-prone plaques are not the 
only vulnerable plaques. All types of atherosclerotic plaques 
with a high likelihood of thrombotic complications and rapid 
progression should be considered as vulnerable plaques. 
Secondly vulnerable plaques are not the only causal factors 
for the development of acute coronary syndromes. Vulner-
able blood (prone to thrombosis) and vulnerable myocar-
dium (prone to fatal arrhythmia) play equally important 
roles. The investigators propose criteria for defining vulner-
able plaque, based on the examination of culprit plaques, and 
markers of vulnerability. Major criteria suggested are active 
inflammation, presence of thin cap with large lipid core, en-
dothelial denudation with superficial platelet aggregation, 
fissured plaque or presence of high grade coronary stenosis. 
Minor criteria are superficial calcified nodule, presence of 
plaque hemorrhage, endothelial dysfunction, or positive re-
modeling of the artery. Markers of vulnerability at the plaque 
level include morphology such as cap thickness, the size of 
lipid core size, the colour of the plaque, collagen content, 
lipid content, stiffness, calcification and flow pattern 
throughout the coronary artery. The presence of features 
which suggest the presence of a vulnerable plaque identifies 
an individual at higher risk of an acute coronary syndrome 
presentation - hence the term 'vulnerable patient'. 
The Vulnerable Patient and Identification by Serum 
Markers 
  The term “vulnerable patient” may be more appropriate 
to clinicians. This concept of a vulnerable patient, combined 
with the wide acceptance of atherosclerosis as a chronic   
inflammatory disease, has resulted in a series of new   
approaches to risk stratification in cardiovascular disease 
detection of serum inflammatory markers, blood throm-
bogenicity and matrix degrading capacity that correlate with 
coronary artery disease [14]. The high-sensitive C-reactive 
protein (hsCRP) is one of the most established serum mark-
ers and is currently available in routine clinical practice. 
CRP is an acute phase protein with a stable baseline concen-
tration which increases during systemic inflammation. Over 
40 clinical studies had investigated the potential association 
of inflammation with cardiovascular disease and the perhaps 
more importantly the ability of hsCRP levels to predict fu-
ture cardiovascular events [15, 16]. The use and interpreta-
tion of hsCRP is however limited by the fact that it is an 
acute phase protein which is elevated in diseases or injuries 
causing inflammation and tissue damage which unfortu-
nately translates into a high false positive rate in the ability 
of hsCRP to predict future cardiovascular events. A meta-
analysis of 22 population-based prospective studies however 
reported an odds ratio of 1.6 with CRP in predicting a car-
diovascular event after correction for several established 
cardiovascular risk factors [17]. In addition, the JUPITER 
investigators have reported that rosuvastatin is equally as 
effective in men and women in reducing major adverse car-
diac events in a population without hyperlipidemia but con-
sidered at increased cardiovascular risk due to an elevated 
hs-CRP [18]. The largest and most comprehensive meta-
analysis to date looking at CRP levels and cardiovascular 
risk, included patients from JUPITER and examined the in-
dividual records of 160 309 people from 54 long-term pro-
spective studies with 48% of the subjects female. The re-
searchers concluded that whilst CRP is unlikely to be a 
causal factor for cardiovascular disease it may help identify 
patients at increased risk who can benefit from early inter-
vention [19]. 
  Other inflammatory markers such as interleukin   
(IL)-6, IL-8, IL-3, Macrophage colony-stimulating factor 
(M-CSF) and soluble CD40 ligand have reported similar 
odds ratios to hsCRP in the ability to improve diagnosis   
over conventional risk factors. Again, these inflammatory 
markers have low positive predictive value due to their low 
specificity. In addition to the inflammatory markers, many 
novel serum markers such as fibrinogen, myeloid-related 
protein 8/14, adiponectin, brain natriuretic peptide and ma-
trix metalloproteinase-9 (MMP-9) have been investigated 
and appear to add little to the Framingham risk score [14, 
20]. 
DIAGNOSIS OF VULNERABLE PLAQUE 
  Despite significant advances in imaging this remains 
problematic. Most current techniques identify luminal di-
ameter or stenosis, wall thickness, and plaque volume but 
remain unable to identify high-risk plaques. High-resolution, 
multicontrast magnetic resonance imaging (MRI) appears to 
currently hold the most promise, particularly of noninvasive 
imaging of high-risk vulnerable or rupture prone plaques. 
The diagnostic modalities currently available  to the cardi-
ologist  and  their usefulness and limitations are listed in   
Table 1. These can essentially be divided into non-invasive 
and invasive techniques. 
NON-INVASIVE MODALITIES 
  The enthusiasm for use of non-invasive modalities to 
help identify vulnerable plaque was inspired by the first 
SHAPE (Screening for Heart Attack Prevention and Educa-
tion) guideline. The investigators observed that most heart 
attacks and strokes occur in people who are not classified at 
high risk by traditional cardiovascular risk factors and there-
fore, proposed non-invasive screening for asymptomatic men 
(45-75years old) and women (55-75 years old) [21]. The 
currently available non-invasive modality used to attempt to 
diagnose the patient with vulnerable plaque are electron-
beam computed tomography (EBCT), multislice CT (MSCT), 
CT coronary angiography (CTA), magnetic resonant imagine 
(MRI) and nuclear techniques such as nuclear scintigraphy, 
positron-emission tomography (PET) and PET-CT. 
  The traditional EBCT is a technique for imaging coro-
nary artery calcium which utilizes a faster rate of image ac-
quisition than conventional computed tomography. How-
ever, it has no proven correlation with plaque vulnerability 
as vulnerable plaque often lacks calcium. MSCT and CTA, 
on the other hand, shows good correlation with coronary 
angiography in assessing stenosis severity, with a sensitivity 
between 93-95%, specificity of 85-90% [20, 22]. In addition, 
MSCT are able to distinguish fibrous-rich from lipid-rich 
plaques and providing more information on plaque morphol-
ogy [23]. In terms of radiation exposure, MSCT is regarded 
as a moderate to high. A recent publication by Smith-
Bindman et al., suggests the risk of this should not be under-
estimated particularly in women. In this retrospective cross –Vulnerable Plaque in CAD  The Open Cardiovascular Medicine Journal, 2011, Volume 5    125 
sectional study the investigators estimated life-time attribut-
able cancer risk associated with imaging and concluded   
one in 270 women who underwent a CT coronary angiogram 
at age 40 will eventually develop cancer as compared to   
one in 600 men [24]. With improved technology and particu-
lary increased acquisition speeds the clinical usefulness   
of MSCT in identifying vulnerable plaque warrants further 
investigation. 
  High-resolution magnetic resonance imagine (MRI) has  
emerged as a potential noninvasive in vivo imaging modality  
for atherosclerotic plaque characterization. MRI differenti- 
ates plaque components on the basis of biophysical and   
biochemical parameters which include chemical composition  
and concentration, water content, physical state, molecular  
motion, or diffusion. In addition, MRI also provides details  
of surrounding tissue in one session. One main advantage of  
MRI over MSCT is the ability to perform imaging without  
ionizing radiation. In addition it can be repeated sequentially  
over time. High-resolution MRI is an excellent tool for visu- 
alizing fibrous cap thickness and rupture in coronary plaques  
[25, 26]. At present, MRI  provides not only a method of   
noninvasively visualizing plaque and discriminating its com- 
ponents but also a way of accurately assessing the effects of  
treatments, such as lipid-lowering therapy, and timing the   
activity of clots to determine when they become inactive.   
These techniques, whilst promising remain experimental. 
  Nuclear imaging which includes PET and PET-CT have 
a higher detection sensitivity than MRI, however, remain 
compromised by relatively lower resolution which impairs 
imaging of small vessels such as coronary arteries. Many 
radiotracers have been developed on the basis of molecules 
and cells involved in atherogenesis. Of note, 18F-Fluoro-2-
DeoxyGlucose (18F-FDG) which normally accumulates 
more quickly in tumour cells has also been observed to ex-
hibit early uptake in plaque macrophages, and as such may 
have a role in non-invasive detection of highly inflamed vul-
nerable plaque [27, 28]. To date, however, no single ra-
diotracer appears ideally suited to image atherosclerosis and 
provide the prognostic and clinical indicators necessary for 
medical and surgical interventions. 
INVASIVE IMAGING MODALITIES 
  Invasive imaging modalities include coronary angiogra-
phy, intravascular ultrasound (IVUS), and optical coherent 
tomography (OCT). Other modalities such as thermography, 
angioscopy, Raman spectrography and near-infrared spec-
trography are currently investigational tools and are not dis-
cussed in this manuscript. 
Coronary Angiography 
  It is well established that, although an individual severe 
coronary stenosis may become acutely occluded, this is a 
more frequent occurrence in less obstructive plaques [29]. 
Indeed, in approximately 70% of patients presenting with 
myocardial infarction, the lesions leading to occlusion have 
been reported as <50% stenotic [1, 29]. In the early phases of 
atherosclerosis the luminal size is not affected by plaque 
growth due to expansion of the external elastic membrane, 
so-called “positive remodeling”. As the plaque grows and 
approaches the lumen, negative remodeling occurs. Positive 
remodeling is also seen in an acute myocardial infarction at 
the site of plaque rupture, whereas negative remodeling and 
Table 1.  Information Provided by Various Imaging Modalities to Identify the Vulnerable Plaque 








Calcium Thrombus Inflam’n Predict 
Events 
Invasive Modalities 
Angiography Degree  of  stenosis  + -  -  - +/-  +/-  -  +/- 
IVUS (Elastography, 
palpography and  
virtual histology) 
Plaque volume, vessel dimensions, 
(plaque deformability and  
composition) 
+ +  +/-  +  + +/-  -  +/- 
Angioscopy Plaque  Color  - -  +  +  - +  -  +/- 
OCT  Plaque architecture and cap thickness  + +  + +  + +  -  ? 
Thermography PlaqueTemperature    -  - ?  ?  ?  ?  +  +/- 
Raman/NIR  Plaque chemical constituents   -  -  +  +  +  -  -  ? 
Non-Invasive Modalidies 
Nuclear Scintigraphy  Plaque  constituents  - -  +  -  - +  -  ? 
EBCT  Predominantly calcium   +  -  -  -  +  -  -  +/- 
MSCT  Vessel  characteristics  + +  + +  + -  -  ? 
MRI  Plaque  volume  + +  + +  + -  -  ? 126    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Liang et al. 
smaller plaque areas may be associated with stable angina 
[30]. This phenomenon of remodeling makes angiography a 
poor technique with which to assess the true atherosclerotic 
disease burden as the shadows of the lumen seen on angi-
ography provide only indirect and incomplete information 
concerning the extent of the atherosclerosis process in the 
arterial wall. 
Intravascular Ultrasound 
  Intravascular ultrasound (IVUS) provides a two-
dimensional cross-sectional image of the arterial wall and 
can accurately assess the plaque burden [31]. On the basis of 
echogenicity, plaques can be differentiated into three catego-
ries as follows: (i) highly echoreflective area corresponding 
to calcified tissue; (ii) hyperechoic areas representing fibro-
sis or (iii) hypoechoic regions corresponding to thrombus or 
lipid-rich tissue [32]. Histopathologic studies mostly report 
low sensitivity and specificity for IVUS in detecting lipid-
rich lesions, and axial resolution remains too low for measur-
ing cap thickness. Efforts have focused on novel methods to 
analyze the integrated backscatter of the signal to improve 
plaque characterization. A commercially available system 
has been developed using this analysis that assigns plaque to 
the categories of fibrotic, fibrofatty, calcific, and necrotic 
core and has been termed “virtual histology” [33]. Another 
addition to conventional IVUS examination is the use of 
elastography. This concept is based on the principle that tis-
sue components can differ in hardness as a result of their 
different histopathologic composition and are expected to be 
compressed differently if a defined pressure is applied. The 
technique can discriminate between soft and hard material 
and can assess the mechanical properties of the vessel wall. 
Hard calcifications will be compressed less than soft lipids 
[34]. The strain images are constructed using the relative 
local displacements and hard and soft regions can be identi-
fied using this technique. With intravascular imaging a de-
rivative of elastography called palpography is used. Elasto-
graphy has the potential to identify plaque vulnerability as 
the detected areas of increased radial strain represent regions 
of high circumferential stress, a feature of plaque vulnerabil-
ity [34]. However, a major problem in advancing intravascu-
lar elastography to cardiac in vivo applications is the acquisi-
tion of data in a pulsating artery located in a contracting 
heart. 
Optical Coherence Tomography  
  Optical coherence tomography (OCT) is analogous to 
IVUS, but measures the intensity of reflected infrared light 
rather than acoustic waves [33, 35]. Studies have shown 
OCT is capable of differentiating lipid tissue and further-
more, the thickness of the fibrous cap overlying an atheroma 
can be well demarcated [33, 35]. However despite wide-
spread use in areas such as ophthalmology there are still 
many limitations of OCT for in vivo intravascular imaging 
including the reduction of image quality through blood or 
large volumes of tissue, the relative slow data acquisition 
rate, and the multiple scattering. The information acquired 
by OCT and IVUS are complimentary as OCT can produce 
high resolution images to help assesss fibrous cap thickness 
and macrophage infiltrations of intact coronary atheroscle-
rotic plaques while IVUS provides details of penetration and 
tissue characterization of the lesions. 
PHYSIOLOGICAL ASSESSMENT 
  Fractional flow reserve (FFR) is increasingly used to 
identify physiological important lesions which angiographi-
cally appear non-flow limiting. It is defined as a ratio of the 
pressure distal to a stenosis in relation to the pressure proxi-
mal to the stenosis under maximum hyperaemia, normally 
induced by either intra-coronary or peripheral adenosine 
infusion. A FFR of 0.75 means that a given stenosis causes a 
25% drop in blood flow pressure which is considered as a 
significant stenosis. The DEFER investigators reported de-
ferral of percutaneous coronary intervention in intermediate 
lesions with an FFR of > 0.75 is safe with a low risk of acute 
coronary syndrome presentations; <1% after 5 years of fol-
low-up [36, 37]. The Fractional Flow Reserve Versus Angi-
ography for Multivessel Evaluation (FAME) trial further 
demonstrated that the use of FFR in patients with multiple 
vessel coronary who are undergoing percutaneous coronary 
intervention with drug-eluting stents significantly reduces 
the mortality, nonfatal myocardial infarction and revasculari-
zation at 1 year compared with angiographically-guided 
group [38]. In addition, Versteeg et al. demonstrated that the 
monocyte toll-like receptors 2 and 4, which are related to 
plaque vulnerability, were significantly higher in patients 
with FFR <0.75 than in patients with an FFR of >0.80. This 
suggests that plaque vulnerability may be preceded by 
ischaemia [39]. To date, there is no clinical trial to date using 
FFR to detect vulnerable plaque per se, therefore, the role of 
FFR in the detection of vulnerable plaques and management 
of vulnerable patients requires further evaluation. 
MANAGEMENT 
  Innovations in both medical therapy and novel interven-
tional techniques have significantly decreased the morbidity 
and mortality associated with coronary atherosclerosis. 
However, detection of vulnerable patients remains elusive; 
as for many individuals, sudden coronary death is the first 
presentation with cardiac disease. For primary prevention, 
the emphasis is on plasma markers and noninvasive testing 
to identify patients at risk. For secondary prevention, interest 
has focused on vulnerable patients with vulnerable plaques 
they may possess that may be identified and treated at   
the time of cardiac catheterization. It is plausible that   
many agents already proven to prevent coronary events by 
reducing plaque vulnerability. 
Systemic Therapy for Vulnerable Plaque 
  The pharmacological therapies of proven benefit in the 
management of vulnerable plaque –related coronary events 
are statins, ACE inhibitors, beta-blockers, aspirin, and cal-
cium-channel blockers [40]. There is no doubt that intense 
lowering of LDL, which may be achieved by statin therapy, 
can prevent clinical events initiated by vulnerable plaques. 
The ASTEROID study reported that a marked reduction in 
LDL was associated with an 11.1% decrease in coronary 
plaque volume as measured by IVUS. It is plausible that 
intense LDL lowering was responsible for this beneficial 
decrease in plaque volume and stabilization of plaques [41]. Vulnerable Plaque in CAD  The Open Cardiovascular Medicine Journal, 2011, Volume 5    127 
Angiotensin-converting enzyme (ACE) inhibitors may im-
prove plaque stability by inhibiting the endothelial dysfunc-
tion and oxygen-free radical production caused by angio-
tensin. In addition, they may also decrease macrophage ac-
tivity and inhibit smooth muscle cell lipoxygenase activity. it 
is possible that the benefit of ACE inhibitors is in part due to 
up-regulation of type III collagen synthesis, or an anti-
atherogenic effect as suggested by the HOPE study sub-
group. These investigators demonstrated a significant reduc-
tion in the rate of carotid intimal medial thickening with 
ramipril [42, 43]. Calcium antagonists may also stabilise 
plaques by interfering with lipid oxidation and reducing 
foam cell formation which accompanies a significant in-
crease in transmembrane calcium transport seen in acute 
coronary syndromes implying an anti-atherogenic role [42]. 
Antithrombotic agents are of established benefit in the man-
agement of acute coronary syndromes, in addition, the Euro-
pean Society for Vascular Surgery guidelines recommended 
the use of antithrombotic agents for both symptomatic and 
asymptomatic carotid stenosis patients in whom vulnerable 
plaques have a role in the disease process [44-46]. These act 
mainly by reducing intravascular haemostasis, but may also 
have a direct passivating effect on the vascular wall. Aspirin 
has antiplatelet and anti-inflammatory properties and has 
demonstrated benefits both as a stand-alone treatment in 
acute coronary syndrome, or in combination with heparin 
and clopidogrel. In addition, as platelets promote the accu-
mulation of inflammatory cells, the antiplatelet aggregation 
activity of Gp IIb/IIIa inhibitors can reduce plaque macro-
phage burden [42]. 
  Many other agents may have a role in the management of 
vulnerable plaques but require further clinical validation 
include antioxidants, folic acid, antibiotics, angiotensin-
receptor blockers, omega-3 fatty acids, cyclooxygenase-2 
inhibitors, influenza vaccine, metalloproteinase inhibitors, 
peroxisome proliferator–activated receptor antagonists, 
Lipoprotein-associated phospholipase A2, darapladib, 
AGI1067 and cholesterol ester transfer protein inhibitors [40, 
42, 47]. 
LOCAL THERAPY FOR VULNERABLE PLAQUE 
  Although systemic therapy is the likely preferred option 
for most individuals, the currently available treatment op-
tions do not provide adequate protection, particularly for the 
very-high-risk patient. The opportunity exists in these indi-
viduals to consider delivery of local preventive therapy in 
addition to systemic therapy at the time of revascularization 
procedures. 
  Local delivery of therapy to the vulnerable plaque may 
be considered particulary if regions at increased risk of a 
clinical cardiac event can be identified. Promising local 
treatment options under investigation include stents with or 
without drugs and photodynamic therapy.  
  Most lesions responsible for acute coronary syndromes 
occur in the proximal part of the major coronary arteries as 
these are regions of shear stress with increased numbers of 
thin-cap fibroatheromas. Stenting, a logical option for issues 
relating to increased mechanical stress is an effective treat-
ment of established coronary disease. Furthermore im-
provements in stent technology continue and are likely to 
reduce the risks associated with stenting and thereby shift the 
risk-to benefit ratio in favour of stenting less severe lesions. 
Drug-eluting stents have been evaluated in an atherosclerotic 
rabbit model as a possible treatment for vulnerable plaques. 
Placement of a stent over lesions in the aorta reduced lipid 
core size and induced formation of an additional fibrous cap 
over the lipid pool. Although these experimental results are 
encouraging, the benefits of stenting angiographically mild 
to moderate lesions on the rationale they contain vulnerable 
plaques must be confirmed in randomized trials. Bioabsorb-
able stents, which may reduce or eliminate the long-term risk 
of stent thrombosis, may be preferable for prophylactic stent-
ing of nonstenotic vulnerable plaques. The challenges of 
identification of the vulnerable plaque therefore remains 
pivotal to the development of local therapeutic solution. 
  Photodynamic therapy has been proposed as a method to 
stabilize a specific plaque or a region of an artery by selec-
tive ablation of macrophages or other targeted cells. The 
photosensitizing agent motexafin lutetium has been tested in 
atherosclerotic rabbits. After photoactivation via an intraaor-
tic catheter, a marked reduction in the number of macro-
phages and a small decrease in atheroma burden without 
damage to normal tissue was observed. Photodynamic ther-
apy has also been demonstrated to reduce neointimal growth 
without suppressing re-endothelialization of a stent in a por-
cine model [48, 49]. The same agent has been administered 
to patients undergoing coronary stenting in a safety study 
and was found to be well tolerated. These early results sug-
gest that photodynamic therapy may eventually have a role 
in the local or regional treatment of vulnerable plaques. 
CONCLUSION 
  Understanding the concept of vulnerable plaques and 
vulnerable patients is helpful in the management and preven-
tion of cardiovascular events. Despite recent advances in 
non-invasive and invasive imaging, identification remains a 
diagnostic challenge. A possible future approach in cardio-
vascular risk prediction and prevention may include tradi-
tional risk factor assessment, biochemical markers and   
affordable non-invasive imaging. Patients identified at high 
risk of plaque rupture-related events may be offered further 
assessment and treatment with high-resolution imaging and 
local therapies such as stenting or photodynamic therapy. 
The early detection of vulnerable patients will hopefully   
lead to early clinical treatment or interventions to prevent a 
life-threatening cardiovascular event. 
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ABBREVIATIONS  
ACE =  Angiotensin  Converting  Enzynme 
CTA  =  Computed Tomographic coronary 
Angiography 
EBCT  =  Electron-Beam Computed Tomography 
FFR =  Fractional  Flow  Reserve 128    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Liang et al. 
hsCRP =  high-sensitive  C-Reactive  Protein 
IL =  InterLeukin 
IVUS =  IntraVascular  UltrouSound 
M-CSF  =  Macrophage Colony-Stimulating Factor 
MMP   =  Matrix MetalloProteinase 
MRI   =  Magnetic Resonance Imaging 
MSCT   =  Multi-Slice Computed Tomography 
OCT  =  Optical Coherent Tomography 
PET =  Positron-Emission  Tomography 
PET-CT = Positron-Emission  Tomography  Com-
puted Tomography 
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